Charles River Associates announced that it has acquired substantially all of the assets of C1 Consulting. C1’s employees, including five key individuals will become CRA vice presidents-Elizabeth Rountree, Rob Sederman, Ned Kitfield, Kevin Brubacher, and Robert Broadnax. Ms. Rountree and Mr. Sederman co-founded C1 Consulting in 2004. Ms. Rountree brings more than 20 years of customer insights experience in biopharmaceuticals and has deep expertise in neuroscience and oncology. Mr. Sederman has more than 25 years of data and analytics expertise in both pharmaceuticals and biotech; he has led C1’s efforts in advanced analytics and will drive this capability at CRA. Mr. Kitfield has held multiple senior commercial leadership roles in global and domestic pharmaceutical companies, including Shire and Sanofi. Mr. Brubacher has 25 years of pharmaceutical and biotech commercialization experience and has led the StrategyPractice since joining C1 in 2010. Mr. Broadnax brings nearly 20 years of pharmaceutical and biotech experience in the areas of commercialization strategy, sales, and customer insights. He has held multiple senior and brand leadership roles at Roche Pharmaceuticals, Bristol-Myers Squibb, and UCB, and has expertise in the areas of oncology, immunology, and virology.
CRA International, Inc. is a global consulting firm specializing in providing economic, financial and management consulting services. It offers consulting services in two areas: litigation, regulatory, and financial consulting and management consulting. It provides consulting services to corporate clients and attorneys in a range of litigation and regulatory proceedings, providing research and analysis, expert testimony, and support in litigation and regulatory proceedings in all areas of finance, accounting, economics, insurance, and forensic accounting and investigations. It also uses its expertise in economics, finance, and business to offer law firms, businesses, and government agencies services. Its management consulting services include strategy development, performance improvement, corporate strategy and portfolio analysis, estimation of market demand, new product pricing strategies, survey and market research, valuation of intellectual property and other assets and others.